AURA Aura Biosciences, Inc. Insider Trading

LP Matrix Capital, a 10% owner, exits entire AURA stake via sale of 6.9M shares.

LP Matrix Capital Management Company, which holds a 10% beneficial stake in Aura Biosciences, has completed a full liquidation of its position by selling approximately 6.9 million shares. This is the fund's second open-market sale in the past three years, following a prior purchase in late 2023 whose outcome remains too recent to evaluate. The stock has appreciated significantly over the past quarter but still trades below its 52-week high, and Aura remains an unprofitable biotech company burning cash with persistent operating losses. The timing coincides with a strong price rally, though without visibility into the fund's specific hold period or acquisition costs, this transaction appears to reflect portfolio rebalancing or capital redeployment by an institutional holder rather than a signal tied to company-specific developments. The complete exit is notable given the fund's substantial ownership size, but the absence of concurrent insider selling by officers or directors limits the ability to draw broader conclusions about management confidence in the business.

CFO Anthony S Gibney purchased 50,000 shares of AURA at $4.90 ($245.0K), raising stake 591.6% to 58,452 shares post-transaction

Gibney Anthony S acquired 50,000 shares at $4.90 on 2025-05-16, increasing his holdings from 8,452 shares to 58,452 shares—a 591.6% increase. This represents a substantial accumulation by a senior executive (filer title omitted per system reporting), with a total outlay of $245,000.00. The magnitude of the position increase and the dollar commitment warrant investor scrutiny into whether this reflects management's assessment of company valuation at this price point. Note: one line item from this filing was excluded from the reported holdings due to a transaction code conflict; the remaining facts reflect the confirmed purchase activity.

Director Johnson David Michael buys 20,000 shares (20.0K) of AURA at $4.90; stock -49.5% from 52-week high but +10.6% over 30 days.

Johnson David Michael purchased 20,000 shares at $4.90 on 2025-05-16, a price near the bottom of the 52-week range ($4.90–$11.74), increasing his holdings by 13.7%. His prior trades at AURA (5 of 5 prior buys) demonstrated strong timing, with all posts showing positive 90-day returns ranging from 8.4% to 20.4%. However, the company is deeply unprofitable with a net income of -$27.5M against a market cap of $298.1M, and the stock has declined 22.5% over the trailing 90 days despite the recent 30-day bounce of +10.6%. The purchase occurs at a severe discount to the 52-week high, but without additional context on company-specific catalysts or operational improvements, the financial deterioration and loss of 49.5% from peak valuations present meaningful headwinds to any recovery thesis.